Abstract
The effect of the nicotinic agonist AG-4 on memory processes was evaluated in the mouse passive avoidance test. AG-4 (100 μg per mouse icv) prevented amnesia induced by scopolamine (1.5 mg kg -1 ip), mecamylamine (20 mg kg -1 ip), and dihydro-β-erythroidine (10 pg per mouse icv). In the same experimental conditions, AG-4 (100 μg per mouse icv) also prevented baclofen (2 mg kg -1 ip), clonidine (0.125 mg kg -1 ip), and diphenhydramine (20 mg kg -1 ip) amnesia in mice. AG-4 exerted an antiamnesic effect comparable to that produced by nicotine (2 mg kg -1 ip), physostigmine (0.2 mg kg -1 ip), and the nootropic drug piracetam (30 mg kg -1 ip). At the active dose, AG-4 did not impair mice motor coordination and spontaneous motility as revealed, respectively, by Rota-rod test and Animex apparatus. Present results evidence the antiamnesic activity of the nicotinic agonist AG-4 suggesting a potential employment of this compound in the symptomatic treatment of cognitive impairments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
